Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment
Background. Juvenile idiopathic arthritis (JIA) is one of the most common rheumatological diseases of childhood. The central place in the problem of JIA belongs to the question of treatment the timeliness and adequacy of which determine the disease prognosis and, in fact, the entire future of the ch...
Main Authors: | T.V. Marushko, O.Ye. Onufreiv, Yu.V. Marushko, O.B. German |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2023-03-01
|
Series: | Zdorovʹe Rebenka |
Subjects: | |
Online Access: | https://childshealth.zaslavsky.com.ua/index.php/journal/article/view/1553 |
Similar Items
-
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
by: Nisha R. Acharya, et al.
Published: (2020-10-01) -
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
by: Sofia Lanz, et al.
Published: (2021-08-01) -
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
by: William D. Renton, et al.
Published: (2019-10-01) -
Successful use of adalimumab as a conservative treatment for bilateral knee lipoma arborescens in patient with psoriatic juvenile idiopathic arthritis – case report and review of literature
by: Marijan Frkovic, et al.
Published: (2022-12-01) -
Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics
by: Mikhail M. Kostik, et al.
Published: (2022-06-01)